UPDATE 2-Hikma sees higher full-year revenue, shares climb [Reuters]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Reuters
UPDATE 2-Hikma sees higher full-year revenue, shares climb | Reuters 4 Min Read * CEO expects rise in overall revenue * Hikes guidance at top two divisions * Shares rise 10 pct (Adds shares, details from CEO call) By Justin George Varghese Aug 15 (Reuters) - London-listed Hikma Pharmaceuticals expects higher full-year revenue after raising forecasts at its top injectables and generics businesses, sending its shares up 10 percent. The Jordanian drugmaker said it sold more injectable opioids in the United States due to a supply shortage, and had a better-than-forecast performance in generics for the first half of the year as its prices proved more resilient than expected. The higher forecast in generics comes as global generic drugmakers with operations in the U.S. cut profit forecasts because of pricing pressure. Novartis said last month that 2018 sales at its generics unit, Sandoz, would fall in the low single-digit percentages, after previously holding out hopes for them to remain st
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Global Pediatric Drugs And Vaccines Market Size To Exceed USD 265.5 Billion By 2033 | CAGR of 8.04% [Yahoo! Finance]Yahoo! Finance
- Myasthenia Gravis (MG) Treatment Industry Forecast to 2030: A $2.5 Billion Market Dominated by Alexion Pharma, Grifols, Avadel Pharma, Novartis, Pfizer, AbbVie, and Roche [Yahoo! Finance]Yahoo! Finance
- Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis [Yahoo! Finance]Yahoo! Finance
- Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosisPR Newswire
- Swiss Watchmakers Fear Retail Glut and Discounts After Boom [BNN Bloomberg (Canada)]BNN Bloomberg
NVS
Earnings
- 1/31/24 - Miss
NVS
Sec Filings
- 2/15/24 - Form S-8
- 2/2/24 - Form SC
- 1/31/24 - Form 6-K
- NVS's page on the SEC website